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ABSTRACT Chronic obstructive pulmonary disease (COPD) is a disabling condition that is
characterised by poorly reversible airflow limitation and inflammation. Acute exacerbations of COPD are a
common cause of hospitalisation and death among COPD patients. Several biochemical markers have been
studied as outcome predictors in COPD; however, their measurement often requires significant time and
resources. Relatively simple biomarkers of inflammation calculated from routine complete blood count
tests, such as the neutrophil to lymphocyte ratio (NLR), might also predict COPD progression and
outcomes. This review discusses the available evidence from studies investigating the associations between
the NLR, COPD exacerbations and death in this patient group.
Introduction
Chronic obstructive pulmonary disease (COPD) affects more than 200 million individuals and is currently
the third leading cause of death worldwide (up from the sixth in 1990), with mortality rates projected to
increase further [1–3]. COPD is a major contributor of healthcare costs due to frequent hospitalisation,
loss of productivity and disability [4]. COPD is a heterogeneous collection of syndromes with complex
pathophysiological mechanisms and different clinical phenotypes, which negatively affect accurate
diagnosis, as well as the design and validation of effective studies and therapies [5–7].
By and large, COPD is characterised by a progressive destruction of the pulmonary tissue, often the result
of an inflammatory response to external stimuli (i.e. long-term exposure to cigarette smoking,
environmental pollution), which culminates in a non-fully reversible airflow limitation [8]. Typical clinical
manifestations include chronic bronchitis, caused by large-airway inflammation and remodelling, and
emphysema, a disease of the distal airways and the lung parenchyma, characterised by loss of alveolar
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respiratory surface. Shortness of breath and chronic productive cough can progress over time to chronic
hypoxaemic and/or hypercapnic respiratory failure [9, 10]. Moreover, COPD is often characterised by
extrapulmonary manifestations, such as systemic inflammation, cardiovascular comorbidities, cancer,
cachexia and muscle dysfunction, osteoporosis, anaemia, depression and anxiety, which also contribute to
disability and premature mortality [9, 11].
Acute exacerbations of COPD (AECOPD), defined as worsening of the patient’s baseline dyspnoea, cough
and/or sputum are an essential component of the natural history of the disease [12]. AECOPD are
associated with increased risk of subsequent exacerbations, worsening of coexisting pathological
conditions, poor performance status and physical activity, deterioration of respiratory function and,
ultimately, death [13]. About half of AECOPD are triggered by bacterial and viral infections; however,
non-infective factors such as environmental pollution can also contribute [14–17]. It is possible that
bacterial colonisation itself, or repetitive and intermittent exacerbation caused by recurrent infections, may
contribute to the chronic inflammatory state and progression of COPD [18]. Inflammation encompasses a
complex network of interactions involving various immune-related cells, including neutrophils and
lymphocytes, which can lead to persistent respiratory tissue injury and damage [19]. Moreover, it is likely
that an excessive inflammatory response against bacteria contributes to chronic inflammation [18–21]. It
has been reported that the absolute counts of key immune-related cell populations in the peripheral blood,
and their ratios, can adequately reflect chronic inflammatory conditions [22–24].
In particular, the neutrophil to lymphocyte ratio (NLR) in peripheral blood is being increasingly studied as
a systemic inflammatory marker, particularly considering its rapid, widely available, and relatively
inexpensive assessment through routine blood count analysis. NLR has been shown to be an independent
prognostic factor in various solid tumours, including lung, colorectal, pancreatic, breast, ovarian and
gastric cancer [25–30]. Furthermore, it has been associated with disease severity, hospitalisation,
malnutrition, recurrences and mortality in various chronic diseases, including cardiovascular and kidney
diseases [31–33]. In recent years, the NLR has also been investigated as diagnostic and prognostic marker
in COPD. Chronic inflammation in COPD causes the recruitment of both the main white blood cell
populations, lymphocytes and neutrophils. The latter, once activated, release neutrophil elastase, cathepsin
G, proteinase-3, matrix metalloproteinase (MMP)-8 and MMP-9, myeloperoxidase (MPO) and human
neutrophil lipocalin, which participate actively in the pathophysiological mechanisms of emphysema and
COPD. For example, neutrophil elastase is able to degrade insoluble elastin and MPO mediates the
bactericidal effects of neutrophils. Furthermore, both neutrophil elastase and MPO favour tissue
destruction in COPD [34, 35]. Therefore, NLR has been investigated as a putative marker of disease
severity and prognosis. In this review, we discuss the results of published studies on the association
between NLR, disease exacerbation and mortality in COPD.
NLR in stable COPD and exacerbations
The use of NLR as a marker in patients with stable COPD or during AECOPD has only been evaluated in
the past few years (table 1). In 2014, GÜNAY et al. [36] investigated the hospital records of 269 COPD
patients with stable disease and acute exacerbations, as well as 50 sex- and age-matched healthy controls.
There was a significant difference in NLR values between healthy controls (mean±SD 1.71±0.65), stable
COPD (2.59±1.79) and AECOPD (4.28±4.12). However, there were no significant differences in relation to
disease severity, both in stable and AECOPD patients. By contrast, there were significant positive
correlations between NLR, C-reactive protein (CRP), and red cell distribution width (RDW), as well as a
negative association between NLR and the mean platelet volume (MPV), both in stable COPD and
AECOPD. Systemic inflammation reduces the survival of erythrocytes and platelets and deforms their
membranes. High RDW and MPV have been associated with increased inflammatory activity in several
diseases [57–60]. This might explain the correlations with NLR found by GÜNAY et al. [36] in patients with
stable COPD, and supports the potential applicability of simple blood count indexes in the clinical
evaluation of the disease.
In another study, FURUTATE et al. [37] enrolled 141 COPD patients to evaluate the association between the
NLR and clinical parameters in stable disease, and to investigate potential changes during exacerbations in
49 patients. The NLR was significantly correlated with the forced expiratory volume in 1 s (FEV1) and the
BODE (BMI, airflow obstruction, dyspnoea, exercise capacity) index, a composite marker of disease in
COPD. There was also a significant correlation between the NLR and the percentage of low-attenuation
area representing emphysematous changes, body mass index (BMI), fat-free mass index, nutritional status
and COPD severity, 6-min walk test and the modified Medical Research Council dyspnoea scale (mMRC)
score, but not with the fat-mass or the Charlson comorbidity index. The associations remained significant
after adjusting for age, sex, Charlson co-morbidity index and smoking status, and suggest the potential role
of the NLR to predict features of COPD severity. In this study, a significant association was also observed
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TABLE 1 Studies investigating the predictive roles of neutrophil to lymphocyte ratio (NLR) in chronic obstructive pulmonary
disease (COPD)
First author [ref.] Patients enrolled Study design Main findings
NLR as predictor of
exacerbations in stable
COPD
GÜNAY [36] COPD: 178 stable, 91
exacerbations; 50 healthy
controls
Retrospective NLR significantly different between controls and COPD
patients, but not between patients with stable COPD
and with exacerbations
FURUTATE [37] COPD: 141 stable, 49 exacerbations Retrospective NLR significantly higher in patients with exacerbations.
Significant correlations with FEV1, BODE, BMI, 6MWT,
mMRC, low-attenuation area and fat-free mass index
LEE [38] 885 COPD, 233 exacerbations
(1 year)
Retrospective NLR significantly higher in patients with exacerbations.
NLR predictor of exacerbations. Significant correlation
with FEV1
TAYLAN [39] COPD: 100 stable with
exacerbation; 80 healthy controls
Retrospective NLR significantly higher in patients with exacerbations,
NLR higher in stable COPD than in controls.
NLR ⩾3.29 predictor of exacerbation
FARAH [40] COPD: 13 stable, 72 exacerbations;
15 healthy controls
Retrospective NLR significantly higher in patients with exacerbations.
NLR ⩾7.3 predictor of exacerbation
KURTIPEK [41] COPD: 94 male patients, 48 with
exacerbations
Prospective NLR significantly higher in exacerbations. NLR ⩾3.3
predictor of exacerbation
BILIR [42] COPD: 467 patients, 186 with
exacerbations; 215 healthy
controls
Retrospective NLR significantly higher in COPD and in exacerbations.
NLR ⩾3.35 predictor of exacerbation
IN [43] COPD: 103 patients, 47 with
exacerbations; 40 healthy
controls
Retrospective NLR significantly higher in COPD and in exacerbations.
NLR ⩾3.34 predictor of exacerbation
NLR as marker of
exacerbation aetiology
(infection)
TANRIVERDI [44] COPD: 77 patients with
exacerbations
Prospective Bacterial infection in 37.4% of the patients. NLR ⩾11.5
significantly associated with bacterial infection
VAN DE GEIJN [45] COPD: 17 stable and 45
exacerbations (22 bacterial and
23 non-bacterial)
Retrospective NLR determined with different methods significantly
higher in exacerbations than in stable, and in bacterial
exacerbations than in non-bacterial ones
NLR in COPD patients with
comorbidities
VAGULIENE [46] 139 lung cancer; COPD: 40 stable
and 55 with lung cancer; 33
healthy controls
Prospective NLR significantly higher in lung cancer patients. No
significant difference in NLR between COPD and
healthy patients
YASAR [47] COPD: 140, 63 with metabolic
syndrome; 50 healthy controls
Retrospective NLR significantly higher in COPD patients than in
controls, NLR significantly higher in those with
metabolic syndrome. NLR ⩾2.56 predictor of COPD
ARISOU [48] COPD: 40 stable; 40 healthy
controls
Prospective NLR was higher in COPD patients than in the control
group. Significant positive correlation between
tricuspid atrial conduction time and NLR
NLR as predictor of
hospitalisation
LEE [49] COPD: 61 stable, 59 exacerbations;
28 healthy controls
Prospective NLR significantly higher in patients with exacerbations.
Significant correlations with mMRC and 6MWT. NLR
⩾2.8 predictor of hospitalisation
NLR as predictor of
re-hospitalisation
DUMAN [50] COPD: 1704 with exacerbations,
351 with >2% eosinophils
Retrospective NLR significantly lower in the eosinophilic group. NLR
predictor of re-admission and death
NLR as predictor of death
RAHIMIRAD [51] COPD: 315, 70 died in hospital Retrospective NLR significantly higher in patients who died in hospital.
NLR ⩾4 predictor of in-hospital death
YAO [52] COPD: 303 with exacerbations,
33 died in hospital
Retrospective NLR significantly higher in patients who died in hospital.
NLR ⩾6.24 predictor of in-hospital death
Continued
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between CRP and NLR. In addition, during exacerbations, the NLR values were significantly elevated when
compared to stable disease.
LEE et al. [49] prospectively measured NLR in 59 patients with COPD exacerbation, 61 patients with stable
disease and 28 healthy controls. NLR values were significantly higher in patients with COPD exacerbation
when compared to those with stable disease and healthy controls (12.4±10.6, 2.4±0.7 and 1.4±0.5,
respectively). The NLR differences between patients with stable COPD and controls were significant using
an unpaired t-test, but not using other statistical tests. Moreover, patients recovering from exacerbations
had a significantly lower NLR value, compared with values during the exacerbations (4.5±4.6 versus
11.5±8.8). Regarding the correlations between NLR and clinical parameters, in 33 patients with stable
COPD and eight with AECOPD, it was found that associations with BMI and FEV1 were not significant,
as opposed to correlations with mMRC score and 6-min walk test. Furthermore, receiver operating curve
(ROC) analysis showed that 2.8 was the optimal NLR cut-off value with maximal sensitivity (60%) and
specificity (60.9%) for hospitalisation. In univariate logistic regression analysis a NLR ⩾2.8 independently
predicted hospitalisation, together with low BMI and FEV1 values. In multivariate analysis a NLR ⩾2.8
remained an independent predictor of hospitalisation. This cut-off value, also assessed in other studies, is
close to values observed in healthy subjects, which might limit its use in clinical practice (table 1, figure 1).
LEE et al. [38] performed a wider study enrolling 885 patients from the Korean COPD Subtype Study
cohort. The study investigated the relationship between the NLR and the severity of airflow limitation,
measured with spirometry (primary outcome) and exacerbations during the first year of follow-up and the
3.3: COPD and exacerbations [42, 43]; 















FIGURE 1 Neutrophil to lymphocyte ratio (NLR) cut-off values in chronic obstructive pulmonary disease
(COPD) identified in the studies reviewed.
TABLE 1 Continued
First author [ref.] Patients enrolled Study design Main findings
XIONG [53] COPD: 368 stable, 96 died during
follow-up; 298 healthy controls
Prospective NLR significantly higher in COPD patients than in
controls. NLR significantly higher in those who died
during follow-up. NLR ⩾3.3 predictor of death
KUMAR [54] COPD: 181 with exacerbation,
16 died within 90 days
Retrospective NLR significantly higher in patients who died within
90 days from exacerbation
SALTÜRK [55] COPD in ICU: 647, 62 with >2%
eosinophils
Retrospective NLR significantly lower in the eosinophilic group.
NLR ⩾16 predictor of death
NLR and oral corticosteroid
therapy in COPD
SØRENSEN [56] COPD: 386, 84 using
glucocorticoids
Prospective NLR significantly lower in patients without
glucocorticoids, NLR predictor of death in patients not
treated with glucocorticoids
FEV1: forced expiratory volume in 1 s; BMI: body mass index; BODE: BMI, airflow obstruction, dyspnoea, exercise capacity; 6MWT: 6-min
walking test; mMRC: modified Medical Research Council dyspnoea scale; ICU: intensive care unit.
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previous year according to NLR quartiles (Q1⩽1.43, 1.43<Q2⩽2.04, 2.04<Q3⩽2.94, and 2.94<Q4). Both
clinical symptoms and quality of life, assessed using the St George’s Respiratory Questionnaire, mMRC
and the COPD assessment test significantly deteriorated with increasing NLR quartiles. In addition,
participants with higher NLR were more likely to have shorter 6-min walk test distance. As the NLR
quartile increased, respiratory functional parameters (FEV1 (%), FEV1 (L), forced vital capacity (FVC; %),
FVC (L), and FEV1/FVC) significantly deteriorated, and inhaled corticosteroids were more commonly
prescribed in the higher NLR group. NLR values were inversely associated with the severity of airflow
limitation determined by FEV1 % predicted and absolute values, also after adjusting for age, sex, BMI,
pack-years of smoking and inhaled corticosteroid use. There were no significant differences in the
prevalence of comorbidities (cardiovascular diseases, diabetes mellitus, gastro-oesophageal reflux disease
and osteoporosis) among the NLR quartiles. This suggests that NLR alterations in COPD are mainly
caused by the disease itself.
With regard to COPD exacerbations during the previous year, patients in the fourth quartile of NLR had
the highest rate of exacerbations. In univariate logistic regression analysis, a one unit increase in NLR was
significantly associated with exacerbation in the first year. In multivariate binary regression, using the first
NLR quartile as reference, the fourth NLR quartile was an independent predictor of exacerbations during
the first year of follow-up after adjusting for demographic, clinical and functional factors. Furthermore, the
predictive ability of NLR during the first year of follow-up (area under the curve (AUC) 0.586, 95% CI
0.528–0.643) was higher than that of white blood cell (WBC) and neutrophil counts. This suggests that the
combination of different blood cell populations, expressed by the NLR, might better reflect the
inflammatory status in COPD.
In a retrospective study of 100 patients with AECOPD, TAYLAN et al. [39] confirmed that the NLR was the
most sensitive indicator of exacerbation by comparing the ROC curves for NLR, CRP, WBC and
erythrocyte sedimentation rate (ERS). In this study, 43 cases were classified as Global Initiative for Chronic
Obstructive Lung Disease (GOLD) III and 57 as GOLD IV. Analyses were carried out 3 months after
AECOPD and during stable disease; a control group of 80 healthy subjects was also studied. The mean
NLR values of controls, stable COPD patients and AECOPD patients were 1.7±0.9, 3.1±2.5 and 7.1±5.4,
respectively (p <0.001). Mean NLR values in AECOPD patients were significantly higher than those of
patients with stable disease and controls, whereas the NLR values of patients with stable COPD were
higher than controls. Pearson correlation analysis showed significant associations between the NLR and
CRP, WBC and ERS. A NLR cut-off value of 3.29, one point higher than that proposed by LEE et al. [49],
showed higher sensitivity (80.8%) and specificity (77.7%) in predicting exacerbations.
Similar results, albeit using a higher cut-off level, were reported in another prospective study by FARAH
et al. [40] in 13 patients with stable COPD, 72 patients with AECOPD and 15 healthy volunteers. In the
AECOPD group the mean NLR values were, in agreement with previous studies, significantly higher than
those of stable COPD patients and controls. Furthermore, there was a positive correlation between NLR
and CRP. Using a NLR cut-off of 7.3, the sensitivity and specificity for AECOPD were 76.8% and 73.1%,
respectively (AUC 0.793).
Three further studies, one prospective and two retrospective, were conducted in Turkey [41–43]. All these
studies included patients with stable COPD and AECOPD, whereas healthy controls were only enrolled in
the two retrospective studies by BILIR et al. [42] and IN et al. [43]. These studies confirmed significantly
higher NLR values in COPD patients when compared to healthy controls, whereas AECOPD patients had
significantly higher NLR values when compared to patients with stable COPD. A positive correlation with
CRP was observed in all studies. The NLR cut-off points predicting exacerbation in these studies were 3.3,
3.34 and 3.35, respectively [41–43].
NLR and infections in COPD exacerbations
TANRIVERDI et al. [44] investigated the ability of NLR to detect infections which trigger AECOPD. The
authors enrolled 77 patients with AECOPD and carried out cultures from tracheal aspirates or sputum on
admission. Bacteria were isolated in 37.4% of patients and the procalcitonin (PCT), CRP and NLR values
between them and the remaining cases were compared. NLR values were significantly higher in patients
with bacterial exacerbation. The cut-off NLR value for predicting bacterial infections was 11.5 (sensitivity
61%, specificity was 58%, AUC 0.58); the AUC of PCT was significantly better in predicting bacterial
exacerbation [44].
VAN DE GEIJN et al. [45] studied 17 stable COPD, 22 bacterial and 23 non-bacterial AECOPD patients.
Patients with AECOPD had significantly higher NLR values when compared to stable patients.
Furthermore, AECOPD patients with bacterial infections had higher NLR values than those with
non-bacterial infections. The authors tested several effective predictive models, most of them including
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NLR. Globally, the studies of TANRIVERDI et al. [44] and VAN DE GEIJN et al. [45] demonstrate that infectious
AECOPD are characterised by higher NLR values, probably due to a more intense inflammatory reaction
involving the neutrophils rather than the lymphocytes.
NLR as a prognostic marker in COPD
The association between NLR and inflammation in COPD patients was investigated in other studies that
focused on its ability to predict in-hospital and post-discharge mortality. RAHIMIRAD et al. [51]
retrospectively reviewed 315 hospital charts of COPD patients in two Iranian hospitals. NLR values were
higher in patients who died in hospital than in those discharged alive. In addition, mortality rates were
higher in patients with NLR ⩾4 than those in patients with NLR <4. After adjusting for age, sex, anaemia
and thrombocytopenia, a binary logistic regression showed that NLR independently predicted in-hospital
mortality. ROC analysis indicated that a NLR with a cut-off value of 4 predicts in-hospital mortality with
87% sensitivity and 40% specificity (AUC 0.717).
In a recent retrospective study, YAO et al. [52] enrolled 303 patients with AECOPD. NLR values were
significantly higher in patients who died in hospital than in those who survived. ROC analysis for using
NLR to predict in-hospital mortality indicated an optimal cut-off of 6.24 (AUC 0.803), with 81.1%
sensitivity and 69.2% specificity. In the entire cohort NLR values correlated positively with serum CRP
levels, while the predictive capacity of NLR exceeded that of CRP and platelet to lymphocyte ratio (PLR)
individually or in combination.
XIONG et al. [53] performed a prospective, multicentre, parallel-group, case–control study in 368 patients
with moderate-to-very severe COPD and 296 controls, assessed every 3 months for 2 years. The baseline
NLR values were significantly higher in COPD patients than in controls (2.98±1.89 versus 2.02±1.92). The
mean NLR values of the 272 patients who survived during the follow-up were lower than those who died.
Both univariate and multivariate analysis showed that NLR independently predicted death. ROC analysis
(AUC 0.91) indicated that a NLR cut-off value of 3.3 predicted mortality with sensitivity of 85.8% and
specificity of 89.7%. According to this cut-off point, COPD subjects were divided into a high NLR group
and a low NLR group; exacerbations and mortality were significantly lower in the latter group. The same
cut-off value was found to predict AECOPD in other studies, as previously discussed.
KUMAR et al. [54] retrospectively studied 181 patients with acute COPD exacerbation. Death occurred in 16
(9%) patients within 90 days and in 32 (18%) patients within 12 months from discharge. The mean NLR
values in patients who died were higher than those of survivors (13±10 versus 7±8). Nevertheless, in this
study multivariable logistic regression analysis showed that NLR was not significantly associated with
mortality at 90 days from discharge, after adjusting for age, haemoglobin, neutrophil count, PLR and urea.
Some studies assessed the prognostic role of NLR in relation to eosinophilic state. In the retrospective
study of SALTÜRK et al. [55], 647 COPD subjects requiring intensive care unit (ICU) admission were
divided into two groups according to their peripheral eosinophil count: 62 in the eosinophilic group
(eosinophils >2%) and 585 in the non-eosinophilic group (eosinophils <2%). Blood NLR on ICU
admission was significantly lower in the eosinophilic group (median (interquartile range) 4.6 (3.2–6.8)),
compared to the non-eosinophilic group (13.0 (17.3–23.1)). Similar findings were observed on discharge
and the difference in NLR between admission and discharge was significantly higher in the
non-eosinophilic group. Logistic regression analysis, after adjusting for age, sex, BMI, peripheral
eosinophilia, long-term oxygen or noninvasive mechanical ventilation applications use, APACHE (Acute
Physiology and Chronic Health Evaluation) II score on admission, presence of arrhythmia, septic shock,
resistant pathogen and CRP >50 mg·mL−1 showed that a NLR >16 independently predicted mortality. This
value is consistently higher than other cut-offs reported in other studies and might reflect the severity of
the patients evaluated (figure 1).
A similar retrospective observational cohort study was conducted by DUMAN et al. [50] in 1704 COPD
patients hospitalised with exacerbations (351 patients with eosinophilic COPD as previously defined).
Similarly, the NLR on admission was significantly higher in the non-eosinophilic group (6.0 (3.65–10.6))
in comparison to the eosinophilic group (3.73 (2.6–5.15)). NLR values in 504 readmitted patients within
6 months after discharge were higher (5.8 (3.5–10.4)) than those of patients not readmitted (4.9 (3.2–8.8)).
The NLR was also higher in those who died in comparison to survivors, in accordance with previous
studies. In addition, Cox regression analysis indicated that a NLR ⩾7 was positively associated with
6-month mortality.
NLR in patients with COPD and other comorbidities
Three studies evaluated the role of NLR in patients with COPD and other comorbidities. VAGULIENE et al.
[46] compared NLR values between 139 patients with lung cancer, 55 with lung cancer and stable COPD,
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40 with stable COPD and 33 healthy individuals. The NLR was significantly higher in lung cancer patients
with COPD (2.92 (0.93–13.42)) or without COPD (3.08 (1.18–8.84)) when compared to non-cancer
patients with COPD (2.35 (1.13–4.25)) or healthy individuals (1.86 (1.16–3.21)). However, the difference
between COPD patients and healthy subjects was not statistically significant in this study.
YASAR et al. [47] recruited 140 patients with COPD, of whom 63 had metabolic syndrome, and 50 sex- and
age-matched healthy controls. Among patients with COPD, the NLR was significantly higher in patients
with metabolic syndrome than those without (3.40±0.93 versus 2.07±0.43). ARISOU et al. [48] studied the
relationship of NLR with atrial conduction time in a case–control study including 40 stable COPD patients
and 40 controls. The authors evidenced that tricuspid atrial conduction time was significantly longer in
COPD patients than in controls (26.4±11.4 ms versus 17.7±7.7 ms), and a significant positive correlation
was identified between tricuspid atrial conduction time and NLR (r=0.38, p<0.001). These findings, as
opposed to those of LEE et al. [38], which suggest that specific comorbidities can influence the kinetics of NLR.
NLR and steroid therapy in COPD
Glucocorticoid therapy is not the mainstay COPD treatment! It is the dual bronchodilation which is the
pivotal treatment of COPD. Inhaled corticoids are only recommended when frequent exacerbations occur
according to GOLD. Nevertheless, this is also questionable and likely that inhaled corticosteroids are
essentially useful in eosinophilic COPD [61]. In most of the studies examined to date detailed data about
the type, dose and regimen used are lacking. An evaluation of NLR temporal changes in relation to
TABLE 2 Studies investigating relationships between neutrophil to lymphocyte ratio (NLR) and other biomarkers in chronic






GÜNAY [36] CRP, PDW, RDW, MPV Increased levels of WBC, CRP, RDW and MPV in COPD. Significant positive correlation of NLR
with CRP and RDW, and negative correlation with MPV in COPD
FURUTATE [37] CRP CRP significantly increased in COPD. Significant positive correlation between NLR and CRP
TAYLAN [39] CRP, WBC, RDW, PDW,
MPV, ESR
Significant correlations with CRP, WBC and ESR. High NLR values in AECOPD patients with low
CRP, WBC or ESR levels
FARAH [40] CRP, WBC, RDW, MPV,
CD64
RDW, CRP and CD64 significantly elevated in AECOPD. Significant correlations of NLR with
CRP and RDW
KURTIPEK [41] CRP, PLR CRP and PLR are significantly higher in AECOPD. Significant positive correlation with CRP. CRP
AUC was better than that of NLR, which was better than AUC for PLR
BILIR [42] CRP Significant positive correlation with CRP. CRP AUC better than AUC for NLR
IN [43] CRP, ESR Significant positive correlation with CRP and ESR
TANRIVERDI [44] CRP, PCT PCT higher in infections. Significant but weak positive correlation with CRP. AUC value of PCT
significantly better in predicting bacterial infection compared with the CRP or the NLR
VAN DE GEIJN [45] CRP, PCT and others CRP and PCT higher in AECOPD, especially bacterial ones. Addition of PCT to CRP increased
specificity for bacterial AECOPD compared to CRP alone
YASAR [47] CRP, RDW, MPV, PDW CRP, RDW and PDW were higher while MPV was lower in COPD. CRP, RDW and PDW were
higher and MPV was lower in patients who had metabolic syndrome
LEE [49] CRP CRP was higher in exacerbations than in healthy controls
DUMAN [50] CRP, platelet/MPV CRP was significantly higher in the non-eosinophilic group. The platelet/MPV ratio was not
different between the two groups. Survival negatively influenced by elevated CRP in the
non-eosinophilic group
RAHIMIRAD [51] dNLR, MLR, PLR dNLR higher in dead patients than in those discharged alive. MLR and PLR not significant in
multivariate analysis
YAO [52] CRP, PLR NLR levels correlated with serum CRP levels in AECOPD. CRP and PLR levels higher in dead
patients than in survivors. CRP AUC higher than that of PLR in predicting death
XIONG [53] ESR, EBR, CRP, RDW EBR higher in COPD than in controls, and in survivors than in dead patients. EBR and CRP are
predictors of mortality, not ESR or RDW
KUMAR [54] PLR, urea PLR significantly associated to 90-days mortality, AUC poor
SALTÜRK [55] CRP, platelet/MPV CRP >50 mg·mL−1 risk factor for mortality
SØRENSEN [56] Calprotectin, YKL-40 Correlation with calprotectin. In the group not treated with systemic glucocorticoids, plasma
calprotectin was significantly associated with mortality. In the group treated with systemic
glucocorticoids, higher plasma YKL-40 was significantly associated with mortality
CRP: C-reactive protein; PDW: platelet distribution width; RDW: red cell distribution width; MPV: mean platelet volume; WBC: white blood cell;
ESR: erythrocyte sedimentation rate; PLR: platelet to lymphocyte ratio; PCT: procalcitonin; dNLR: derived neutrophil to lymphocyte ratio; MLR:
monocyte to lymphocyte ratio; EBR: eosinophil to basophil ratio; AECOPD: acute exacerbation of COPD; AUC: area under the curve.
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glucocorticoid therapies adopted was conducted by SØRENSEN et al. [56] in 386 patients with
moderate-to-very severe stable COPD followed up for 10 years. The patients were divided into two groups
according to systemic glucocorticoid use (the specific type of medications is not reported). Median NLR at
baseline was lower in the group not treated with glucocorticoids (2.83 (2.03–4.57)) compared to that with
glucocorticoid therapy (5.79 (4.17–9.66)). Furthermore, in this study the NLR was significantly associated
with higher mortality in patients without systemic glucocorticoid treatment.
Future perspectives
In recent years, there has been an increasing interest in the potential clinical use of several inflammatory
indexes obtained from routine complete blood count tests. In particular, the NLR has been evaluated in a
range of pathological conditions, including chronic inflammatory and neoplastic diseases, as a diagnostic
marker, an indicator of the intensity of the inflammatory background, and a predictor of the clinical
evolution and prognosis of the disease. There are several features which make such indexes particularly
attractive for clinical use, including their relatively simple derivation and low associated cost, and wide
availability in laboratory practice and healthcare settings. This suggests the possible clinical utility and
potential applications of NLR in COPD. In our review, the NLR correlated well with other markers of
disease severity and predicted AECOPD and mortality, particularly in specific subgroups such as patients
with an elevated eosinophilic state (table 2). Nevertheless, some methodological issues (most studies are
retrospective) and the variability of the patient characteristics and comorbidities in different studies do not
allow an immediate application of the NLR current clinical practice. Furthermore, data regarding
traditional glucocorticoids and other COPD medications, such as long-acting β-agonists, long-acting
muscarinic antagonists, phosphodiesterase-4 inhibitors and antibiotics [62, 63], are lacking in most of the
studies evaluated. Despite the overall promising results in terms of predictive capacity, larger multicentre
prospective studies with longer follow-up, in patients with various phases of the disease and different
therapies, are required to better define the clinical role of the NLR in COPD. The latter also mandates the
need for the identification and validation of specific NLR cut-off values for diagnosis, disease progression,
response to therapy and prognosis.
Conclusions
Blood NLR is a simple, inexpensive, widely available index which has been intensively evaluated in recent
years in several clinical applications and in various diseases, including COPD. The studies reviewed
showed that the NLR is a valuable predictor of AECOPD and mortality. Furthermore, it correlates well,
and in some studies is even more accurate, than other traditional inflammatory indexes (WBC counts
alone) or more complex and expensive markers (CRP and calprotectin). Additionally, several NLR cut-off
values have been identified in several clinical situations (stable COPD, exacerbations and ICU patients),
and with different prediction purposes (COPD itself, exacerbation, infection, and in hospital and general
mortality). The routine use of the NLR in clinical practice should be further assessed in large,
well-designed, prospective studies.
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